SCIASCIA THOMAS
SEC insider (Form 3/4/5 filer). CIK 0001229946. Chief Scientific Officer at Trevi Therapeutics, Inc. (TRVI). 6 reported Form 4/5 transactions since Sep 2024; latest on Feb 19, 2026. Located in NEW HAVEN, CT.
Companies SCIASCIA THOMAS has filed insider reports for
- Trevi Therapeutics, Inc. (TRVI): Officer, Chief Scientific Officer
SCIASCIA THOMAS
CIK: 0001229946
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Trevi Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Feb 19, 2026TRVI
Trevi Therapeutics, Inc.
AwardDirectStock Option (right to buy)
85K shares- - May 31, 2025TRVI
Trevi Therapeutics, Inc.
AwardDirectPerformance Stock Option (right to buy)
60K shares- - Mar 25, 2025TRVI
Trevi Therapeutics, Inc.
ExerciseDirect2.6K shares at avg. $1.43$4K - Mar 25, 2025TRVI
Trevi Therapeutics, Inc.
SaleDirect2.6K shares at avg. $6.60$17K - Mar 10, 2025TRVI
Trevi Therapeutics, Inc.
AwardDirectPerformance Stock Option (right to buy)
32K shares- - Feb 18, 2025TRVI
Trevi Therapeutics, Inc.
AwardDirectStock Option (right to buy)
116K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 19, 2026 | TRVI Trevi Therapeutics, Inc. | Award Stock Option (right to buy) | 85,000 | - | - | Direct |
| May 31, 2025 | TRVI Trevi Therapeutics, Inc. | Award Performance Stock Option (right to buy) | 60,000 | - | - | Direct |
| Mar 25, 2025 | TRVI Trevi Therapeutics, Inc. | Exercise | 2,631 | $1.43 | $3,762 | Direct |
| Mar 25, 2025 | TRVI Trevi Therapeutics, Inc. | Sale | 2,631 | $6.60 | $17,365 | Direct |
| Mar 10, 2025 | TRVI Trevi Therapeutics, Inc. | Award Performance Stock Option (right to buy) | 32,000 | - | - | Direct |
| Feb 18, 2025 | TRVI Trevi Therapeutics, Inc. | Award Stock Option (right to buy) | 116,000 | - | - | Direct |
1-6 of 6 transactions